Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-82.36%
operating margin TTM
-82.78%
revenue TTM
1.34 Million
revenue per share TTM
0.55$
valuation ratios | |
|---|---|
| pe ratio | -1.10 |
| peg ratio | -0.10 |
| price to book ratio | 0.43 |
| price to sales ratio | 1.07 |
| enterprise value multiple | -1.80 |
| price fair value | 0.43 |
profitability ratios | |
|---|---|
| gross profit margin | 11.64% |
| operating profit margin | -82.78% |
| pretax profit margin | -82.36% |
| net profit margin | -82.36% |
| return on assets | -29.51% |
| return on equity | -32.91% |
| return on capital employed | -32.71% |
liquidity ratios | |
|---|---|
| current ratio | 6.08 |
| quick ratio | 5.28 |
| cash ratio | 1.52 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 86.26 |
| operating cycle | 107.93 |
| days of payables outstanding | 1.04 |
| cash conversion cycle | 106.89 |
| receivables turnover | 16.84 |
| payables turnover | 349.88 |
| inventory turnover | 4.23 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | -407.16 |
| cash flow to debt ratio | -4.24 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.36 |
| cash per share | 1.46 |
| operating cash flow per share | -0.35 |
| free cash flow operating cash flow ratio | 1.03 |
| cash flow coverage ratios | -4.24 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -30.03 |
Frequently Asked Questions
When was the last time BioNexus Gene Lab Corp. (NASDAQ:BGLC) reported earnings?
BioNexus Gene Lab Corp. (BGLC) published its most recent earnings results on 14-08-2026.
What is BioNexus Gene Lab Corp.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. BioNexus Gene Lab Corp. (NASDAQ:BGLC)'s trailing twelve months ROE is -32.91%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. BioNexus Gene Lab Corp. (BGLC) currently has a ROA of -29.51%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did BGLC's net profit margin stand at?
BGLC reported a profit margin of -82.36% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is BGLC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.08 in the most recent quarter. The quick ratio stood at 5.28, with a Debt/Eq ratio of 0.03.